ORGO Organogenesis Holdings Inc.
$1.49▼ -2.61%
Healthcare
Other
After hours
$1.50▲ +0.70%
Sep 11, 7:38 PM ET
Volume 844.1K
Avg Volume (10D) 715.8K
Key Metrics & Fundamentals
Market Cap
$191.73M
P/E Ratio
–
Div Yield
–%
52W Range
1.47 - 7.08
% vs 50 MA
-27.66%
% vs 200 MA
-49.72%
RSI-14
31.0
MACD Histogram
+0.0000
Beta (1Y vs SPY)
1.21
Free Cash Flow
-$32.75M
Gross Rev
$42.81M
Gross Profit
$19.13M
EBITDA
-$46.78M
COGS
$23.67M
Operating Exp
$71.31M
Operating Income
-$52.18M
EBIT
-$52.18M
Pretax Income
-$50.88M
Net Income
-$96.27M
EPS (Diluted)
-0.77
Price & Volume History
Loading chart…
Recent News

Organogenesis (ORGO) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 13, 2026 11:46 PM
Organogenesis Holdings (ORGO) Stock Fair Value Moves Lower After Guidance Cut And Analyst Caution
Simply Wall St. · Aug 10, 2026 5:10 AM
Organogenesis Holdings (ORGO) Is Down 21.5% After Slashing 2026 Guidance And Launching Equity Offering – Has The Bull Case Changed?
Simply Wall St. · Aug 8, 2026 8:12 AM
Organogenesis Holdings Inc. Q2 2026 Earnings Call Summary
Moby · Aug 7, 2026 12:30 PM
Organogenesis Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 7:04 AM
Organogenesis: Q2 Earnings Snapshot
Associated Press · Aug 6, 2026 9:22 PM
Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 6, 2026 8:05 PM
Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
GlobeNewswire · Jul 27, 2026 8:05 PM
Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
GlobeNewswire · Jul 9, 2026 11:30 AM
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
GlobeNewswire · Jul 6, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See ORGO's money flow as a full page
Social Sentiment
Avg +1.00 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.